Patents by Inventor Andreas Zirlik

Andreas Zirlik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST MAC-1
    Publication number: 20210179717
    Abstract: The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.
    Type: Application
    Filed: February 15, 2021
    Publication date: June 17, 2021
    Inventors: Andreas ZIRLIK, Dennis WOLF, Karlheinz PETER
  • Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
    Patent number: 10994010
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 4, 2021
    Assignees: UNIVERSITAETSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Antibodies against Mac-1
    Patent number: 10919967
    Abstract: The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: February 16, 2021
    Assignees: ALBERT-LUDWIGS-UNIVERSITÄTFREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • SELECTIVE TARGETING OF THE CD40L/MAC-1 INTERACTION BY SMALL PEPTIDE INHIBITORS AND ITS USE FOR THE TREATMENT OF INFLAMMATION AND ATHEROGENESIS
    Publication number: 20200093924
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Inventors: Andreas ZIRLIK, Dennis WOLF, Karlheinz PETER
  • ANTIBODIES AGAINST MAC-1
    Publication number: 20190161550
    Abstract: The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.
    Type: Application
    Filed: June 13, 2017
    Publication date: May 30, 2019
    Inventors: Andreas ZIRLIK, Dennis WOLF, Karlheinz PETER
  • SELECTIVE TARGETING OF THE CD40L/MAC-1 INTERACTION BY SMALL PEPTIDE INHIBITORS AND ITS USE FOR THE TREATMENT OF INFLAMMATION AND ATHEROGENESIS
    Publication number: 20180021430
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Application
    Filed: September 20, 2017
    Publication date: January 25, 2018
    Inventors: Andreas ZIRLIK, Dennis WOLF, Karlheinz PETER
  • Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
    Patent number: 9808522
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis
    Publication number: 20140147445
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Application
    Filed: August 17, 2011
    Publication date: May 29, 2014
    Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURG
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter